Literature DB >> 25502048

Pathophysiology and treatment of motion sickness.

John F Golding1, Michael A Gresty.   

Abstract

PURPOSE OF REVIEW: Motion sickness remains bothersome in conventional transport and is an emerging hazard in visual information technologies. Treatment remains unsatisfactory but advances in brain imaging, neurophysiology, and neuropharmacology may provide insights into more effective drug and behavioural management. We review these major developments. RECENT
FINDINGS: Recent progress has been in identifying brain mechanisms and loci associated with motion sickness and nausea per se. The techniques have included conventional neurophysiology, pathway mapping, and functional MRI, implicating multiple brain regions including cortex, brainstem, and cerebellum. Understanding of the environmental and behavioural conditions provocative of and protective against motion sickness and how vestibular disease may sensitize to motion sickness has increased. The problem of nauseogenic information technology has emerged as a target for research, motivated by its ubiquitous applications. Increased understanding of the neurophysiology and brain regions associated with motion sickness may provide for more effective medication in the future. However, the polysymptomatic nature of motion sickness, high interindividual variability, and the extensive brain regions involved may preclude a single, decisive treatment.
SUMMARY: Motion sickness is an emerging hazard in information technologies. Adaptation remains the most effective countermeasure together with established medications, notably scopolamine and antihistamines. Neuropharmacological investigations may provide more effective medication in the foreseeable future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25502048     DOI: 10.1097/WCO.0000000000000163

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  26 in total

Review 1.  The Neurophysiology and Treatment of Motion Sickness.

Authors:  Andreas Koch; Ingolf Cascorbi; Martin Westhofen; Manuel Dafotakis; Sebastian Klapa; Johann Peter Kuhtz-Buschbeck
Journal:  Dtsch Arztebl Int       Date:  2018-10-12       Impact factor: 5.594

2.  Motion Sickness Susceptibility and Baseline Vestibular and Ocular-Motor Performance in Adolescent Athletes.

Authors:  R J Elbin; Anthony P Kontos; Alicia Sufrinko; Mallory McElroy; Katie Stephenson-Brown; Samantha Mohler; Nathan R D'Amico; Michael W Collins
Journal:  J Athl Train       Date:  2019-08-27       Impact factor: 2.860

3.  Assessment of Sea Sickness in Naval Personnel: Incidence and Management.

Authors:  Arvind K Gupta; B Vijaya Kumar; Renu Rajguru; K D Parate
Journal:  Indian J Occup Environ Med       Date:  2021-07-09

Review 4.  Antihistamines for motion sickness.

Authors:  Nadine Karrim; Ryan Byrne; Nombulelo Magula; Yougan Saman
Journal:  Cochrane Database Syst Rev       Date:  2022-10-17

5.  Muscarinic receptor subtypes differentially control synaptic input and excitability of cerebellum-projecting medial vestibular nucleus neurons.

Authors:  Yun Zhu; Shao-Rui Chen; Hui-Lin Pan
Journal:  J Neurochem       Date:  2016-02-15       Impact factor: 5.372

6.  The brain-penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion-induced emesis in Suncus murinus (house musk shrew).

Authors:  Longlong Tu; Zengbing Lu; Man P Ngan; Francis F Y Lam; Claudio Giuliano; Emanuela Lovati; Claudio Pietra; John A Rudd
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

7.  Motion sickness diagnostic criteria: Consensus Document of the Classification Committee of the Bárány Society.

Authors:  Yoon-Hee Cha; John F Golding; Behrang Keshavarz; Joseph Furman; Ji-Soo Kim; Jose A Lopez-Escamez; Måns Magnusson; Bill J Yates; Ben D Lawson
Journal:  J Vestib Res       Date:  2021       Impact factor: 2.354

8.  Opioid-Induced Nausea Involves a Vestibular Problem Preventable by Head-Rest.

Authors:  Nadine Lehnen; Fabian Heuser; Murat Sağlam; Christian M Schulz; Klaus J Wagner; Masakatsu Taki; Eberhard F Kochs; Klaus Jahn; Thomas Brandt; Stefan Glasauer; Erich Schneider
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

9.  Electrocortical therapy for motion sickness.

Authors:  Qadeer Arshad; Niccolo Cerchiai; Usman Goga; Yuliya Nigmatullina; R Ed Roberts; Augusto P Casani; John F Golding; Michael A Gresty; Adolfo M Bronstein
Journal:  Neurology       Date:  2015-09-04       Impact factor: 9.910

10.  Ondansetron and promethazine have differential effects on hypothermic responses to lithium chloride administration and to provocative motion in rats.

Authors:  Drielle D Guimaraes; Paul L R Andrews; John A Rudd; Valdir A Braga; Eugene Nalivaiko
Journal:  Temperature (Austin)       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.